A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
Biomarker discovery in the field of risk prediction in chronic kidney disease (CKD) embraces the prospect of improving our ability to risk stratify future adverse outcomes and thereby guide patient care in a new era of personalised medicine. However, many studies that report biomarkers predictive of...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-11-01
|
Series: | Biomarker Insights |
Online Access: | https://doi.org/10.1177/1177271920976146 |
id |
doaj-03a919bc227f44be9b76278245044f07 |
---|---|
record_format |
Article |
spelling |
doaj-03a919bc227f44be9b76278245044f072020-12-03T04:33:24ZengSAGE PublishingBiomarker Insights1177-27192020-11-011510.1177/1177271920976146A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease ProgressionIbrahim Ali0Sara T Ibrahim1Rajkumar Chinnadurai2Darren Green3Maarten Taal4Tony D Whetton5Philip A Kalra6Division of Cardiovascular Sciences, University of Manchester, Manchester, UKInternal Medicine and Nephrology Department, University of Alexandria, Alexandria, EgyptDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, UKDepartment of Acute Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, UKFaculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UKDivision of Cancer Sciences, University of Manchester, Manchester, UKDivision of Cardiovascular Sciences, University of Manchester, Manchester, UKBiomarker discovery in the field of risk prediction in chronic kidney disease (CKD) embraces the prospect of improving our ability to risk stratify future adverse outcomes and thereby guide patient care in a new era of personalised medicine. However, many studies that report biomarkers predictive of CKD progression share a key methodological limitation: failure to characterise patients’ renal progression precisely. This weakens any observable association between a biomarker and an outcome poorly defined by a patient’s change in renal function over time. In this commentary, we discuss the need for a better approach in this research arena and describe a compelling strategy that has the advantage of offering robust and meaningful biomarker exploration relevant to CKD progression.https://doi.org/10.1177/1177271920976146 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ibrahim Ali Sara T Ibrahim Rajkumar Chinnadurai Darren Green Maarten Taal Tony D Whetton Philip A Kalra |
spellingShingle |
Ibrahim Ali Sara T Ibrahim Rajkumar Chinnadurai Darren Green Maarten Taal Tony D Whetton Philip A Kalra A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression Biomarker Insights |
author_facet |
Ibrahim Ali Sara T Ibrahim Rajkumar Chinnadurai Darren Green Maarten Taal Tony D Whetton Philip A Kalra |
author_sort |
Ibrahim Ali |
title |
A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression |
title_short |
A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression |
title_full |
A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression |
title_fullStr |
A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression |
title_full_unstemmed |
A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression |
title_sort |
paradigm to discover biomarkers associated with chronic kidney disease progression |
publisher |
SAGE Publishing |
series |
Biomarker Insights |
issn |
1177-2719 |
publishDate |
2020-11-01 |
description |
Biomarker discovery in the field of risk prediction in chronic kidney disease (CKD) embraces the prospect of improving our ability to risk stratify future adverse outcomes and thereby guide patient care in a new era of personalised medicine. However, many studies that report biomarkers predictive of CKD progression share a key methodological limitation: failure to characterise patients’ renal progression precisely. This weakens any observable association between a biomarker and an outcome poorly defined by a patient’s change in renal function over time. In this commentary, we discuss the need for a better approach in this research arena and describe a compelling strategy that has the advantage of offering robust and meaningful biomarker exploration relevant to CKD progression. |
url |
https://doi.org/10.1177/1177271920976146 |
work_keys_str_mv |
AT ibrahimali aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT saratibrahim aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT rajkumarchinnadurai aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT darrengreen aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT maartentaal aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT tonydwhetton aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT philipakalra aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT ibrahimali paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT saratibrahim paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT rajkumarchinnadurai paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT darrengreen paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT maartentaal paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT tonydwhetton paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression AT philipakalra paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression |
_version_ |
1724401337177735168 |